(本文来自第一财经) 联环药业公告，经财务部门经初步测算，预计公司2025年度归属于上市公司股东的净利润为负值，2025 年度经营业绩将出现亏损。 ...

Core Viewpoint - Lianhuan Pharmaceutical (600513) announced that it expects a negative net profit attributable to shareholders for the fiscal year 2025, indicating an anticipated operating loss for that year [1] Financial Performance - The company is in the process of accelerating its financial accounting work to comply with the regulations of the Shanghai Stock Exchange [1] - A formal earnings forecast for 2025 will be disclosed as soon as possible, with the final financial data to be confirmed in the official 2025 annual report [1]

Core Viewpoint - Lianhuan Pharmaceutical (600513.SH) announced that its financial department has conducted preliminary calculations, predicting a negative net profit attributable to shareholders for the fiscal year 2025, indicating an expected operational loss for that year [1] Financial Performance - The company anticipates a net profit for 2025 to be negative, suggesting a decline in financial performance [1]

Core Viewpoint - Lianhuan Pharmaceutical (600513.SH) announced that its financial department has conducted preliminary calculations, predicting a negative net profit attributable to shareholders for the fiscal year 2025, indicating an expected operational loss for that year [1] Financial Performance - The company anticipates a net profit for 2025 to be negative, suggesting a decline in financial performance [1]

二、公司在注册有效期内可分期发行科技创新债券，接受注册后如需备案发 行，应事前先向交易商协会备案。公司应按照有权机构决议及相关管理要求，进 行发行管理。发行完成后，公司应通过交易商协会认可的途径披露发行结果。 公司将严格按照有关法律法规、交易商协会相关自律管理规定及上述通知书 的要求，充分考虑公司资金需求和市场情况，在注册有效期内择机发行中期票据， 并按照《非金融企业债务融资工具注册发行规则》、《非金融企业债务融资工具注 册工作规程》、《非金融企业债务融资工具信息披露规则》及有关规则指引规定， 履行信息披露义务。敬请广大投资者注意投资风险。 特此公告。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 江苏联环药业股份有限公司（以下简称"联环药业"或"公司"）于 2025 年 7 月 24 日召开第九届董事会第十二次临时会议，于 2025 年 8 月 11 日召开 2025 年第一次临时股东会，审议通过了《关于公司拟发行科技创新债券的议案》，同 意公司向中国银行间市场交易商协会（以下简称"交易商协会"）申请注册发行 规模最高不超 ...

格隆汇1月14日丨联环药业(600513.SH)公布，公司于近日收到交易商协会出具的《接受注册通知书》 （中市协注〔2026〕MTN2号），决定接受公司科技创新债券注册。现就有关事项公告如下： 一、公司本次注册基础品种为中期票据，注册金额为5亿元，注册额度自本通知书落款之日起2年内有 效，由南京银行股份有限公司和江苏银行股份有限公司联席主承销。二、公司在注册有效期内可分期发 行科技创新债券，接受注册后如需备案发行，应事前先向交易商协会备案。公司应按照有权机构决议及 相关管理要求，进行发行管理。发行完成后，公司应通过交易商协会认可的途径披露发行结果。 ...

一、公司本次注册基础品种为中期票据，注册金额为5亿元，注册额度自本通知书落款之日起2年内有 效，由南京银行股份有限公司和江苏银行股份有限公司联席主承销。二、公司在注册有效期内可分期发 行科技创新债券，接受注册后如需备案发行，应事前先向交易商协会备案。公司应按照有权机构决议及 相关管理要求，进行发行管理。发行完成后，公司应通过交易商协会认可的途径披露发行结果。 格隆汇1月14日丨联环药业(600513.SH)公布，公司于近日收到交易商协会出具的《接受注册通知书》 （中市协注〔2026〕MTN2号），决定接受公司科技创新债券注册。现就有关事项公告如下： ...

证券代码：600513 证券简称：联环药业 公告编号：2026-002 江苏联环药业股份有限公司 关于 2025 年度业绩预亏的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 江苏联环药业股份有限公司（以下简称"公司"）财务部门经初步测算， 预计公司 2025 年度归属于上市公司股东的净利润为负值，2025 年度经营业绩 将出现亏损。 截至本公告披露日，公司生产经营一切正常，敬请投资者理性投资，注意 投资风险。 特此公告。 江苏联环药业股份有限公司董事会 2026 年 1 月 15 日 1 公司将严格遵循《上海证券交易所股票上市规则》等相关规定，加快推进 财务核算工作，尽快披露 2025 年度业绩预告。最终财务数据请以公司正式披露 的 2025 年年度报告为准。 ...

Core Viewpoint - Lianhuan Pharmaceutical experienced a stock price surge, reaching the daily limit on January 9, indicating strong market interest and potential investor confidence in the company [1]. Group 1: Company Overview - Lianhuan Pharmaceutical's primary business encompasses pharmaceutical manufacturing and distribution [3]. Group 2: Industry Developments - The Guangzhou Municipal Government has issued a plan titled "Guangzhou Accelerates the Construction of an Advanced Manufacturing Powerhouse (2024-2035)," which emphasizes the acceleration of innovative drug strategies and the development of monoclonal antibodies, vaccines, blood products, and diagnostic reagents in the biopharmaceutical sector [3]. - The plan aims to address major health issues and advance cutting-edge biotechnologies, targeting breakthroughs in gene engineering, new drug targets and mechanisms, synthetic biology, and bioinformatics [3]. - Leveraging the unique advantages of Lingnan traditional Chinese medicine, the initiative seeks to promote the standardization and internationalization of traditional medicine, creating a comprehensive industrial chain from raw materials to pharmaceuticals [3]. - By 2035, the goal is to establish a leading position in the biopharmaceutical and high-end medical device industries, with an industrial scale reaching 500 billion [3].

Core Viewpoint - The pharmaceutical sector is experiencing significant stock price increases, with notable gains in several companies, indicating positive market sentiment and potential investment opportunities [1]. Group 1: Company Performance - Weikang Pharmaceutical has seen its stock price rise by over 15% [1]. - Frontline Bio and Shanghai Yizhong have both increased by over 10% [1]. - Other companies such as Lianhuan Pharmaceutical, Hongbo Pharmaceutical, Zhixiang Jintai, and Chengda Pharmaceutical are also experiencing upward trends in their stock prices [1].